Clinical trials: Nociplastic Pain
Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
- Trial name
- NCT05652907
- Testing
- FSD201
- Where
- 3 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Quantum Biopharma